Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06650514
Title A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma (Osteomyc)
Acronym Osteomyc
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vall d'Hebron Institute of Oncology
Indications
Therapies
Age Groups: child | senior | adult
Covered Countries ESP


No variant requirements are available.